Chengdu Easton Biopharmaceuticals Co. Ltd. has described lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of cancer.
Merck KGaA has divulged proteolysis targeting chimeras (PROTACs) compounds comprising an E3 ubiquitin ligase binding agent coupled to methionine aminopeptidase-2 (MNPEP; MetAP2) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, osteoporosis, diabetes, obesity, malaria and benign prostatic hyperplasia, among others.
Gilead Sciences Inc. has identified protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Wuhan LL Science & Technology Development Co. Ltd. has synthesized mannan-binding lectin serine protease 2 (MASP2) inhibitors reported to be useful for the treatment of lupus nephritis and IgA nephropathy, among others.
Adlai Nortye Pharmaceutical Co. Ltd. has disclosed Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Ceramedix Holding LLC has been awarded a phase IIB Small Business Innovation Research (SBIR) grant valued at approximately US$3 million by the National Institute of Allergy and Infectious Diseases (NIAID) to support the evaluation of the non-clinical pharmacology of its lead drug candidate. The anti-ceramide antibody is in development through the National Institutes of Health (NIH) as a potential therapeutic to mitigate and/or treat illness due to radiation exposure.
Radiopharm Theranostics Ltd. has entered into an expanded agreement with Terthera BV under which Terthera will supply Radiopharm with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary monoclonal antibody to form RAD-402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression.
Mu opioid receptors (MOR) agonists exert strong anti-nociceptive activity but their ability to cause tolerance and physical dependence are serious issues of concern and limit their use. The activation of another branch of opioid receptors discovered lately, the opioid-related nociceptin receptor 1 (OPRL1) has recently shown the ability to enhance MOR agonist-induced analgesia while limiting tolerance and side effects.
Microtubule-associated serine/threonine kinase-like (MASTL) is involved in cell proliferation, migration, and invasion and for that reason is considered a relevant therapeutic target for cancer treatment. At the recent ACS Fall meeting, researchers from Pfizer Inc. presented the discovery and characterization of a series of potent and selective MASTL inhibitors for the treatment of cancer.
Imunon Inc. has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for the evaluation of the immunogenicity and efficacy of two Imunon DNA-based Lassa virus vaccine candidates. Under the 3-year agreement, the NIAID will assess the efficacy of Placcine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.
RSS
